PD1
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Classical Hodgkin's Lymphoma
Conditions
Relapsed/Refractory Classical Hodgkin's Lymphoma
Trial Timeline
Mar 30, 2017 → Nov 30, 2019
NCT ID
NCT03114683About PD1
PD1 is a phase 2 stage product being developed by Innovent Biologics for Relapsed/Refractory Classical Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03114683. Target conditions include Relapsed/Refractory Classical Hodgkin's Lymphoma.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Classical Hodgkin's Lymphoma were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03114683 | Phase 2 | Completed |
Competing Products
20 competing products in Relapsed/Refractory Classical Hodgkin's Lymphoma